Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed.
View Article and Find Full Text PDFThe effect of 5% and 10% povidone-iodine antiseptic concentrations on postoperative sensorineural hearing loss in tympanoplasty: a triple-blind randomized clinical trial.
Eur Arch Otorhinolaryngol
March 2025
Otolaryngology Research Center, Department of Otolaryngology-Head and Neck Surgery, Tehran University of Medical Sciences, Imam Khomeini Medical Complex, Tehran, Iran.
Purpose: To evaluate the ototoxicity of povidone iodine (PVP-I) at concentrations of 5% and 10% during tympanoplasty by assessing frequency-specific audiometric outcomes and graft success rates in a large cohort of patients.
Methods: This prospective, triple-blinded, randomized clinical trial enrolled 542 patients undergoing primary tympanoplasty. After excluding patients for inadequate follow-up, 204 ears received 10% PVP-I and 199 ears received 5% PVP-I.
Long Term Results of a Phase II Study of Adjuvant Proton Radiotherapy for Node-Positive Cancer of the Uterus and Cervix: Proton Radiation for Uterine/Cervical Cancer.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Purpose/objective(s): Patients with node-positive (LN+) uterine or cervical cancer often require post-operative radiation (RT) to the pelvis and para-aortic nodes. A prospective phase II study was conducted to evaluate the efficacy of proton beam RT for LN+ uterine or cervical cancer.
Materials/methods: Patients with IIIC uterine and cervical cancer post hysterectomy and lymphadenectomy were eligible.
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis.
Eur J Haematol
March 2025
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Background: Data on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited.
Objectives: This study aimed to develop a prognostic model incorporating BM findings and clinico-laboratory factors affecting OS.
Methods: We retrospectively evaluated 50 adults with sHLH and developed a clinicopathological prognostic model based on survival-associated factors.
Incidental High-Grade Sellar Solitary Fibrous Tumor Mimicking Non-Functioning Pituitary Adenoma: A Case Report and Literature Review.
Am J Case Rep
March 2025
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA.
BACKGROUND Sellar solitary fibrous tumors (SFT) are uncommon brain tumors belonging to the fibroblastic and myofibroblastic category of the 2021 World Health Organization (WHO) Classification of Central Nervous System (CNS) Tumors. Twenty-two instances of sellar WHO grade II and III SFT (SFT II/III) have been reported since 1983. SFTs II/III clinical and imaging findings resemble non-functioning pituitary adenomas (NFPAs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!